US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Moderna, Inc. - Common Stock (NQ:MRNA)

225.00 +28.00 (+14.21%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
Via ACCESS Newswire
News headline image
Should You Buy Moderna Before Feb. 13? ↗
The biotech has momentum as its quarterly report approaches. 
Via The Motley Fool
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a... 
Via Finterra
Topics ETFs Economy Initial Public Offering
Which S&P500 stocks have an unusual volume on Thursday? ↗
Via Chartmill
News headline image
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Tom Gardner's 2026 Outlook: Volatility, Government Scrutiny, and Two AI-Adjacent Stocks ↗
Tom Gardner outlines two selective AI opportunities and a disciplined portfolio framework for the next three to five years. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
From Defiance ETFs
Via GlobeNewswire
Gapping S&P500 stocks in Monday's session ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
Dr. David Berman to Join Moderna as Chief Development Officer
Via ACCESS Newswire
News headline image
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
Via ACCESS Newswire
News headline image
3 ETFs Catapulting Beyond the S&P to Start the Year ↗
Via MarketBeat
Topics ETFs Stocks
News headline image
This Stock Is Already Up 58% This Year. Is It a Buy? ↗
This forgotten pandemic stock hasn't said its last word. 
Via The Motley Fool
Monday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Monday. ↗
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
1 Volatile Stock to Own for Decades and 2 We Ignore
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
MarketBeat Week in Review – 01/19 - 01/23 ↗
Via MarketBeat
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
Which S&P500 stocks are moving on Friday? ↗
Via Chartmill
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
Which S&P500 stocks are moving before the opening bell on Friday? ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally
In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for... 
Via MarketMinute
Topics Intellectual Property
Stay informed about the most active stocks in the S&P500 index on Thursday's session. ↗
Via Chartmill
Top S&P500 movers in Thursday's session ↗
Via Chartmill
News headline image
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Moderna Stock Explodes To New 52-Week High: What&#39;s Driving The Action? ↗
Moderna Inc (NASDAQ: MRNA) stock is trading higher Thursday morning, hitting a new 52-week high after new cancer trial data. 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >